1YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| TL02-59 | 3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide | 1315330-17-6 |
| WRG-28 | WRG-28 | 1913291-02-7 |
| FGFR1/DDR2 inhibitor 1 | FGFR1/DDR2 inhibitor 1 | 2308497-58-5 |
| SRI 31215 TFA | SRI-31215 BIS-TFA SALT | 1832686-44-8 |
| CLK-IN-T3 | CLK inhibitor T3 (T3) | 2109805-56-1 |
| MAZ51 | CS-2885 | 163655-37-6 |
| AZD7507 | CS-2850 | 1041852-85-0 |
| JH-VIII-157-02 | 化合物 T15612 | 1639422-97-1 |
| PRN1008 | 瑞扎布鲁替尼 | 1575596-29-0 |
| ARQ 531 | ARQ-531 | 2095393-15-8 |
| TIE-2/VEGFR-2 kinase-IN-1 | 6-(4-甲氧基苯基)呋喃并[2,3-D]嘧啶-4-胺 | 453590-24-4 |
| Pralsetinib | BLU-667（拉西替尼） | 2097132-94-8 |
| trans-Pralsetinib | cis-Pralsetinib hydrochloride (cis-BLU-667 hydrochloride) | 2097132-93-7 |
| cFMS Receptor Inhibitor II | CFMS RECEPTOR INHIBITOR II | 959860-85-6 |
| AGL-2263 | AG 2263 | 638213-98-6 |
| AZD3229 Tosylate | AZD3229 Tosylate | 2248003-71-4 |
| Ningetinib Tosylate | 对甲苯磺酸宁格替尼 | 1394820-77-9 |
| 3-Hydroxy Midostaurin | CGP52421 | 179237-49-1 |
| INDY | INDY | 1169755-45-6 |
| KB SRC 4 | 1-[3-[1-([1,1'-Biphenyl]-3-ylMethyl)-1H-1,2,3-triazol-5-yl]phenyl]-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine | 1380088-03-8 |
| SU16f | 化合物 T16947 | 251356-45-3 |
| PF-06465469 | PF 06465469 Discontinued See A191400 | 1407966-77-1 |
| Vorolanib | VOROLANIB | 1013920-15-4 |
| Acrizanib | 化合物ACRIZANIB | 1229453-99-9 |
| Vecabrutinib | 维卡布鲁替尼 | 1510829-06-7 |
| Conteltinib | CONTELTINIB (CT-707) | 1384860-29-0 |
| Lanraplenib succinate | Lanraplenib (succinate) | 1800047-00-0 |
| Tivozanib | 替沃扎尼 | 475108-18-0 |
| ENMD-2076 | 6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺 | 934353-76-1 |
| Ibrutinib D5 | 伊布替尼布D5 | 1553977-17-5 |
| A-770041 | A-770041 | 869748-10-7 |
| SPP-86 | 1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | 1357349-91-7 |
| BMS-509744 | N-(5-((5-(4-乙酰基哌嗪-1-甲酰基)-4-甲氧基-2-甲基苯基)硫基)噻唑-2-基)-4-(((3,3-二甲基丁烷-2-基)氨基)甲基)苯甲酰胺 | 439575-02-7 |
| JNJ-38877618 | JNJ-38877618 | 943540-74-7 |
| FN-1501 | 1429515-59-2 | 1429515-59-2 |
| PDGFRα kinase inhibitor 1 | PDGFRα kinase inhibitor 1 | 2209053-93-8 |
| Jaspamycin | JASPAMYCIN | 22242-96-2 |
| Nintedanib Ethanesulfonate Salt | 尼达尼布乙磺酸盐 | 656247-18-6 |
| Lck inhibitor 2 | 3-[[4-[(5-羟基-2-甲基苯基)氨基]-2-嘧啶基]氨基]苯甲酰胺 | 944795-06-6 |
| Osteogenic Growth Peptide (10-14) | OSTEOGENIC GROWTH PEPTIDE (10-14) | 105250-85-9 |
| AZ-Dyrk1B-33 | 3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine | 1679330-37-0 |
| RU-301 | RU-301 | 1110873-99-8 |
| Tyrphostin AG1433 | Tyrphostin AG1433 | 168835-90-3 |
| Pazopanib Hydrochloride | 盐酸帕唑帕尼 | 635702-64-6 |
| PF-04217903 methanesulfonate | PF 04217903 MESYLATE | 956906-93-7 |
| Lyn-IN-1 | 巴非替尼 | 887650-05-7 |
| Cabozantinib S-malate | 苹果酸卡博替尼 | 1140909-48-3 |
| Pivanex | (2,2-二甲基-1-氧代丙氧基)丁酸甲酯 | 122110-53-6 |
| R406 | 6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮苯磺酸盐 | 841290-81-1 |
| DPH | 5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮 | 484049-04-9 |
| Lck Inhibitor | 6-(2,6-二甲基苯基)-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-嘧啶并[5',4':5,6]嘧啶并[1,2-A]苯并咪唑-5(6H)-酮 | 847950-09-8 |
| UNC2025 hydrochloride | UNC2025 盐酸盐 | 2070015-17-5 |
| TAS-115 mesylate | TAS-115 MESYLATE | 1688673-09-7 |
| Gilteritinib hemifumarate | GILTERITINIB FUMARATE | 1254053-84-3 |
| BT-13 | BT-13 | 924537-98-4 |
| Y15 | 1,2,4,5-苯四胺四盐酸盐 | 4506-66-5 |
| Bozitinib | BOZITINIB (PLB-1001) | 1440964-89-5 |
| Hck-IN-1 | Nef-IN-B9 | 1473404-51-1 |
| UNC2541 | UNC2541 | 1612782-86-1 |
| TAM-IN-2 | TAM-IN-2 | 2135642-56-5 |
| Petunidin chloride | 矮牵牛素PT | 1429-30-7 |
| Syk-IN-1 | 1,2,4-Triazine-6-carboxamide, 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(1H-indol-7-ylamino)- | 1491150-77-6 |
| PRN694 | 1575818-46-0 | 1575818-46-0 |
| Mirk-IN-1 | 1386979-55-0 | 1386979-55-0 |
| Brigatinib | 布格替尼 | 1197953-54-0 |
| Remibrutinib | LOU-064 | 1787294-07-8 |
| Orelabrutinib | 奥布替尼 | 1655504-04-3 |
| SKLB4771 | FLT3-IN-1 | 1370256-78-2 |
| Dubermatinib | TP-0903 | 1341200-45-0 |
| S49076 | CS-2684 | 1265965-22-7 |
| PRT-060318 | PRT-060318 | 1194961-19-7 |
| Alectinib Hydrochloride | 艾乐替尼盐酸盐 | 1256589-74-8 |
| Src Inhibitor 3 | Src Inhibitor 3 | 2380027-49-4 |
| (Rac)-IBT6A | 1412418-47-3 | 1412418-47-3 |
| Fostamatinib | 福他替尼 | 901119-35-5 |
| Fostamatinib disodium hexahydrate | 福他替尼钠盐水合物 | 914295-16-2 |
| Cediranib maleate | 西地尼布马来酸盐 | 857036-77-2 |
| Taletrectinib | DS-6051b | 1505515-69-4 |
| BIIB068 | BIIB068 | 1798787-27-5 |
| VEGFR-2-IN-6 | 帕唑帕尼杂质3 | 444731-47-9 |
| NVP-BHG712 isomer | NVP-BHG712 isomer | 2245892-85-5 |
| MK-8033 | MK-8033 | 1001917-37-8 |
| MK-8033 hydrochloride | 3-(1-甲基-1H-吡唑-4-基)-5-氧代-N-(2-吡啶基甲基)-5H-苯并[4,5]环庚三烯并[1,2-B]吡啶-7-甲烷磺酰胺盐酸盐 | 1283000-43-0 |
| CP-547632 | 3-[(4-溴-2,6-二氟苄基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]异噻唑-4-甲酰胺 | 252003-65-9 |
| CP-547632 hydrochloride | CP-547632 (hydrochloride) | 252003-71-7 |
| BAY-474 | 化合物BAY-474 | 1033767-86-0 |
| Infigratinib phosphate | NVP BGJ398 磷酸盐 | 1310746-10-1 |
| RET-IN-3 | 化合物 RET-IN-3 | 2414374-53-9 |
| LDN-192960 | 3-[(2,7-二甲氧基吖啶-9-基)硫基]丙胺 | 184582-62-5 |
| LDN-192960 hydrochloride | LDN-192960 HYDROCHLORIDE | 2309172-48-1 |
| AC710 | N-[4-[[[[5-(叔丁基)-3-异恶唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 | 1351522-04-7 |
| Nocodazole | 诺考达唑 | 31430-18-9 |
| CH6953755 | CH6953755 | 2055918-71-1 |
| CA-4948 | 4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)- | 1801344-14-8 |
| AZM475271 | 476159-98-5 | 476159-98-5 |
| I-OMe-Tyrphostin AG 538 | I-OME-AG 538 | 1094048-77-7 |
| BO-264 | BO-264 | 2408648-20-2 |
| DCC-3014 | DCC3014 | 1628606-05-2 |
| RET V804M-IN-1 | 化合物RET V804M-IN-1 | 2414909-94-5 |
| PLX647 | 10MG | 873786-09-5 |
联系方式
